[Form 4] Jazz Pharmaceuticals plc Insider Trading Activity

Rhea-AI Filing Summary

Jazz Pharmaceuticals plc director reports share sales and RSU grant. A board member of Jazz Pharmaceuticals filed a Form 4 disclosing several open-market sales of ordinary shares on November 18, 2025 at weighted average prices ranging from $180.0859 to $182.6009. Following these transactions, the reporting person directly beneficially owned 390,826 ordinary shares.

On November 20, 2025, the director received 2,506 restricted stock units at a price of $0.0 under Jazz’s 2007 Amended and Restated Non-Employee Directors Stock Award Plan, increasing direct beneficial ownership to 393,332 ordinary shares. Each unit represents a contingent right to one ordinary share and, subject to continuous service and certain additional conditions, will vest in full on July 24, 2026.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

COZADD BRUCE C

(Last) (First) (Middle)

5TH FL, WATERLOO EXCHANGE

WATERLOO RD

(Street)

DUBLIN 4 L2

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Jazz Pharmaceuticals plc [ JAZZ ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	11/18/2025		S		3,384	D	$180.0859(1)	405,442	D
Ordinary Shares	11/18/2025		S		8,382	D	$180.8794(2)	397,060	D
Ordinary Shares	11/18/2025		S		5,517	D	$181.8146(3)	391,543	D
Ordinary Shares	11/18/2025		S		717	D	$182.6009(4)	390,826	D
Ordinary Shares	11/20/2025		A(5)		2,506	A	$0.0	393,332	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $179.4013 to $180.38. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

2. Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $180.4028 to $181.385. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

3. Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $181.41 to $182.30. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

4. Reflects the sale of ordinary shares executed in multiple transactions at prices ranging from $181.59 to $182.77. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

5. These restricted stock units are granted pursuant to the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on July 24, 2026.

	By: /s/Paz Dizon, as attorney in fact For: Bruce C Cozadd	11/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Jazz Pharmaceuticals (JAZZ) report in this Form 4?

The filing reports multiple open-market sales of Jazz Pharmaceuticals plc ordinary shares on November 18, 2025 at weighted average prices between $180.0859 and $182.6009, plus a grant of 2,506 restricted stock units on November 20, 2025.

How many Jazz Pharmaceuticals (JAZZ) shares does the reporting person now beneficially own?

After the reported transactions, the director directly beneficially owns 393,332 ordinary shares of Jazz Pharmaceuticals plc, including the 2,506 newly granted restricted stock units.

At what prices were Jazz Pharmaceuticals (JAZZ) shares sold by the director?

The ordinary shares were sold in multiple transactions on November 18, 2025 at weighted average prices of $180.0859, $180.8794, $181.8146, and $182.6009, each reflecting trades within specified price ranges.

What are the terms of the 2,506 restricted stock units granted by Jazz Pharmaceuticals (JAZZ)?

The 2,506 restricted stock units were granted under Jazz’s 2007 Amended and Restated Non-Employee Directors Stock Award Plan. Each unit represents a contingent right to receive one ordinary share and will vest in full on July 24, 2026, subject to continuous service and certain additional conditions.

What is the reporting person’s relationship to Jazz Pharmaceuticals (JAZZ)?

The reporting person is a director of Jazz Pharmaceuticals plc and filed the Form 4 as a single reporting person with direct ownership of the disclosed securities.

Were the Jazz Pharmaceuticals (JAZZ) insider transactions part of a single-day activity?

The sales of ordinary shares occurred on November 18, 2025, while the grant of 2,506 restricted stock units took place on November 20, 2025, as two separate transaction dates.